Roche Holding's supplemental biologics license application for Tecentriq plus chemotherapy (abraxane and carboplatin) as a first-line therapy for patients with metastatic non-squamous non-small cell lung cancer has been accepted by the FDA for review. The agency has set a PDUFA date of Sept. 2.
Roche's sBLA for Tecentriq plus chemo accepted for FDA review
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.